ReviewBiomedicines2024

Clinical Outcomes and Molecular Predictors of Pembrolizumab (Keytruda) as a PD-1 Immune Checkpoint Inhibitor in Advanced and Metastatic Cervical Cancer: A Systematic Review and Meta-Analysis.

Lavinia Balan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.